DGAP-Adhoc: BB Biotech AG publishes its interim report

2020. július 24., péntek, 07:00





DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report


BB Biotech AG publishes its interim report


24-Jul-2020 / 07:00 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Media release of July 24, 2020



Interim report of BB Biotech AG as at June 30, 2020



BB Biotech AG publishes its interim report



BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2020, which covers the results of its business activities for the first six months of 2020.



Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2020 amounted to CHF 422 mn (profit of CHF 554 mn in H1 2019). In the second quarter a profit of CHF 1"180 mn (loss of CHF 336 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.



BB Biotech AG"s interim report as at June 30, 2020 can be downloaded at www.bbbiotech.com.




For further information:

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch




www.bbbiotech.com



Company profile

BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.



Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.











24-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

























Language: English
Company: BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 1100723





 
End of Announcement DGAP News Service




1100723  24-Jul-2020 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=1100723&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.

Közzétételek - archívum